News and Updates

New research challenges traditional age-based healthcare, suggesting biological markers are better predictors for preventive care and disease risk.

Discover the future of the global CRO market through 2034. Explore key trends, AI integration, and the growth of clinical trial outsourcing in healthcare.

The FDA has greenlit the first human trial for a novel oral MS drug, marking a potential shift toward more convenient, targeted neuro-inflammatory care.

Discover how evolving clinical trial data and molecular breakthroughs are shaping modern breast cancer treatment protocols and improving patient outcomes.

New study uses Natera’s ctDNA technology to monitor advanced skin cancer patients, aiming to improve treatment accuracy through precision oncology.

Protalix BioTherapeutics reveals its Q2 2026 financial status and progress on its lead rare disease pipeline. Get the latest update on their clinical growth.

BD has launched the PREVENT trial to advance tissue regeneration technology. Discover how this clinical study aims to transform surgical repair outcomes.

Arch Biopartners is expanding its LSALT peptide clinical trials into the US to combat organ inflammation. Discover how this therapy targets DPEP-1.

Discover how Daraxonrasib’s revolutionary resistance mapping is setting a new standard for oncology trial design, patient stratification, and survival.

When a CRO fails an FDA inspection, clinical sites face severe consequences. Learn how to protect your trial integrity and manage regulatory risks.